How does Low-Dose Aripiprazole (LDA) work differently from psychiatric doses?

At psychiatric doses (10 to 30 mg), aripiprazole acts as a postsynaptic dopamine blocker. At ultra-low doses (0.1 to 2.0 mg), it functions as a presynaptic D2/D3 partial agonist, stimulating dopamine tone and calming microglial neuro-inflammation in the brain without antipsychotic dopamine suppression.

What were the findings of the Stanford University ME/CFS LDA study?

In a 101-patient study published in the Journal of Translational Medicine by Dr. Hector Bonilla and Dr. Chheda, 74% of ME/CFS patients experienced significant clinical improvement in brain fog, physical stamina, and sensory overload at a median dose of 1.0 mg daily.

What should a patient do if LDA loses efficacy after several months?

Up to 20% of patients experience mild tolerance (the 'poop-out' effect). Clinical protocols recommend taking a brief drug holiday of 3 to 5 days, then resuming at a slightly lower maintenance dose (e.g., 0.5 mg to 0.75 mg) to restore presynaptic receptor sensitivity.

Low-Dose Aripiprazole (LDA) Microglial Reset Protocol: 0.1 to 2.0 mg

The Biphasic Hormetic Curve: Why Less is More

Aripiprazole exhibits a strict biphasic dose-response curve. At standard psychiatric doses (10–30 mg), it blocks postsynaptic dopamine receptors. At ultra-low doses (0.1 to 2.0 mg), it binds with high affinity to presynaptic dopamine D2/D3 autoreceptors and 5-HT1A receptors. This stimulates dopamine synthesis and release in the ventral striatum while downregulating pro-inflammatory microglial cytokines (TNF-α, IL-1β). Exceeding 2.0 mg destroys this therapeutic window and causes severe paradoxical sedation and dysphoria PMID: 33526049.

The Stanford University Cohort Findings

In a landmark study published in the Journal of Translational Medicine (2021), clinicians at the Stanford Medicine Chronic Fatigue Clinic evaluated 101 ME/CFS patients treated with LDA:

74%

Overall Response Rate

75 of 101 patients demonstrated measurable, meaningful clinical improvement.

1.0 mg

Median Maintenance Dose

Most responders stabilized between 0.5 mg and 1.5 mg daily.

Top Gains

Primary Symptom Relief

Brain fog, physical stamina, post-exertional malaise, and sensory hypersensitivity.

🧠

Low-Dose Aripiprazole Micro-Titration Engine

Configure an evidence-based, slow titration schedule and calculate exact liquid oral syringe volumes (1 mg/mL commercial liquid).

Clinical Severity & Sensory Overload

Formulation Method

Target Maintenance Dose

Akathisia / Jitteriness Sensitivity

Starting Day 1 Dose

0.25 mg (0.25 mL)

Step-Up Interval

Every 14–21 Days

Target Maintenance

1.0 mg / Day

Dosing Time

Morning (With Breakfast)

Graduated Titration Schedule

Timeframe	Daily Dosage	Oral Syringe Volume (1 mg/mL)	Clinical Action & Monitoring

Clinical LDA Protocol Exhibit

Managing the "Poop-Out" Effect & Drug Holidays

Presynaptic Receptor Resensitization Protocol

Approximately 15% to 20% of patients experience a gradual waning of therapeutic efficacy after 3 to 6 months of continuous daily dosing. This does not represent disease worsening, but rather dopamine D2 autoreceptor desensitization.

The 3-to-5 Day Washout: Discontinue LDA completely for 3 to 5 consecutive days. Because aripiprazole has an elimination half-life of ~75 hours, receptor density resets without acute withdrawal.
Step-Down Re-Entry: Resume LDA at half the previous maintenance dose (e.g., if you were at 1.0 mg, resume at 0.5 mg daily). Most patients recover full efficacy at the lower dose.

Peer-Reviewed References & Clinical Sources

Chheda S, Bonilla H, et al. Treatment of myalgic encephalomyelitis/chronic fatigue syndrome with low dose aripiprazole. J Transl Med. 2021;19(1):47. PMID: 33526049
Kato TA, et al. Aripiprazole inhibits intracellular Ca2+ elevation in activated microglia: Evidence for neuroprotective properties. Neuropsychopharmacology. 2008;33(7):1676-1685. PMID: 17700688
Stip E, Tourjman V. Aripiprazole in dementia and brain injury: Evidence for neuroprotection beyond psychosis. Neuropsychiatr Dis Treat. 2010;6:577-586.